Logo
RUTGERS CANCER INSTITUTE IN THE NEWS APRIL 2022
Delivered by Corporate Media Relations
Fullintel Daily Digest
Service Lines
Fullintel Daily Digest
Rutgers Cancer Institute Names New Chief of Bone Marrow Transplant and Cellular Therapies
Apr 30 | Online Publication  |  Reach: 1,061,170 | Sentiment : Positive
Share article :  |  |  | 
Healio - Ira Braunschweig, MD, has been appointed as section chief of transplant and cell therapy at Rutgers Cancer Institute of New Jersey. Braunschweig will also serve as chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and director for cell therapy and bone marrow transplantation at Robert Wood Johnson University Hospital. Read More
Rutgers Biomedical and Health Sciences Leaders Top Rankings of Most Influential Health Care Leaders in New Jersey
Article image
Apr 01 | Organization| Zach Hosseini  |  Reach: 277,543 | Sentiment : Positive
Share article :  |  |  | 
Rutgers University - Leaders from Rutgers Biomedical and Health Sciences (RBHS) were named at the top of NJBIZ  Health Care Power 50 list, which ranks the top influencers in health care in New Jersey. Rutgers New Jersey Medical School Dean Robert Johnson (1), RBHS Chancellor and Rutgers Executive Vice President for Health Affairs Brian Strom (2), Rutgers School of Public Health Dean Perry N. Halkitis (3), and Rutgers Cancer Institute of New Jersey Director Steven Libutti (8) led a list that also included Rutgers alums Barry Ostrowsky, CEO of the university’s clinical partner RWJBarnabas Health, and New Jersey Commissioner of Health Judith Persichilli. Read More
First-Recorded Treatment of Pregnant Lymphoma Patient With Checkpoint Inhibitor
Apr 19 | Online Publication| Megan Brooks  |  Reach: 690,419 | Sentiment : Neutral
Share article :  |  |  | 
MDedge - “Long story short, the patient did amazing. She carried the pregnancy to term and delivered spontaneously at 38 weeks,” said Dr. Andrew M. Evens of Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, New Brunswick. “She had a bone marrow transplant about three months after delivery. Now almost a year later, both mother and baby are doing fantastic,” he told Reuters Health by phone. (Subscription Required) Read More
Help Cancer Patients Overcome Transportation Barriers
Apr 25 | Online Publication  |  Reach: 266 | Sentiment : Positive
Share article :  |  |  | 
HealthNewsDigest.com - Further supporting Rutgers Cancer Institute of New Jersey’s goal of providing world class patient-centered care, the American Cancer Society has awarded Rutgers Cancer Institute $60,000 in patient transportation and lodging grants, which will help alleviate the financial burden of transportation and lodging costs for cancer patients. Read More
Minority Representation in Clinical Trials Is Critical
Apr 04 | Online Publication  |  Reach: 10,314,250 | Sentiment : Neutral
Share article :  |  |  | 
New Jersey Patch - Addressing disparities in cancer care, including access to and participation in clinical trials, has long been a priority for Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health. Sanjay Goel, MD, MS, director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute shares more. "Ensuring people from diverse backgrounds participate in clinical trials is key to advancing health equity. There are many benefits from having a higher enrollment of minority participants in clinical trials," he says. Read More
Melanoma and Soft-Tissue Cancer Specialist Joins Clara Maass Medical Center
Article image
Apr 29 | Online Publication| Carrie Snow  |  Reach: 1,493,932 | Sentiment : Positive
Share article :  |  |  | 
TAPinto.net - We are pleased to announce that Franz Omar Smith, MD, MAcM, FACS, Surgical Oncology, and Melanoma and Soft Tissue Oncology, is now seeing patients in the Cancer Center at Clara Maass Medical Center, Continuing Care Building, 1 Clara Maass Drive, Belleville, NJ. Dr. Smith takes a patient-centered approach to melanoma and soft-tissue cancer care, with a focus on patient education and shared decision making. He works collaboratively with members of the oncology team, including gastroenterologists, medical oncologists, radiologists, pathologists, radiation oncologists and dermatologists to ensure optimal patient outcomes. He is board certified in Complex General Surgical Oncology. Read More
Pet Companionship During the Cancer Journey
Article image
Apr 04 | Online Publication  |  Reach: 10,314,250 | Sentiment : Neutral
Share article :  |  |  | 
New Jersey Patch - Rutgers Cancer Institute of New Jersey offer forms of pet therapy for cancer patients. Diane L. Haley, MSW, LCSW, OSW-C, director of Patient Experience at Rutgers Cancer Institute of New Jersey shares more about providing patient-centered care through interaction with furry friends. "Pet therapy is a guided interaction between a person and a trained animal. Such interaction also may help them cope better with their emotions," he says. Rutgers Cancer Institute also works with RWJBarnabas Health's Prevention and Recovery's Hope and Healing Program to provide patients with visits from furry four-legged friends including during Patient Experience Week. Read More
Skin Self Examination Among Skin Cancer Survivors
Article image
Apr 05 | Online Publication  |  Reach: 10,314,250 | Sentiment : Positive
Share article :  |  |  | 
New Jersey Patch - With the aid of a $3 million National Cancer Institute grant (R01CA2645-01), Rutgers Cancer Institute of New Jersey researchers aim to enhance the effectiveness of a digital intervention that supports skin self-examination for survivors of melanoma, the deadliest form of skin cancer. The project is based on a previous Rutgers Cancer Institute research study that resulted in the development of an internet-based intervention called mySmartSkin, designed to help to promote regular, thorough checks of the skin for survivors with high risk of recurrence of the disease. The study, led by principal investigators Sharon Manne, PhD, chief of Behavioral Science at Rutgers Cancer Institute of New Jersey and Carolyn J. Heckman, PhD, co-leader of the Cancer Prevention and Control Program at Rutgers Cancer Institute, aims to enhance mySmartSkin with more interactive features using stakeholder engagement. Read More
Rep. Payne Pushes for Cancer Screening Bill in Name of His Late Father
Article image
Apr 18 | Online Publication| Eric Kiefer  |  Reach: 10,314,250 | Sentiment : Neutral
Share article :  |  |  | 
New Jersey Patch - Colorectal cancer affects hundreds of thousands of Americans each year. And according to U.S. Rep. Donald Payne Jr. of New Jersey – who lost his father to the disease – people shouldn't have to worry about how they're going to pay for screenings that may save their lives one day. Standing alongside health care leaders at Newark Beth Israel Medical Center last week, Payne – a Newark resident who represents the state's 10th District – called on Congress to pass the Donald Payne Sr. Colorectal Cancer Detection Act. According to the Newark Beth Israel Medical Center Colorectal Cancer Screening Taskforce, colon cancer is the second most-common cause of cancer-related death in men and women in the United States. Read More
Also syndicated in:
Montclair Patch and West Orange Patch
Syndicated Reach: TM - 206,285,500
New cancer treatments coming to Jersey Shore University Medical Center
Apr 12 | Online Publication| Michael L. Diamond  |  Reach: 788,181 | Sentiment : Neutral
Share article :  |  |  | 
Asbury Park Press - Hackensack Meridian last summer teamed up with a physician group to form the Toms River Regional Cancer Center. Its competitor, RWJBarnabas Health, has announced plans to open a campus in Tinton Falls that would include a center operated by the Rutgers Cancer Institute of New Jersey. Hackensack Meridian last summer teamed up with a physician group to form the Toms River Regional Cancer Center. Its competitor, RWJBarnabas Health, has announced plans to open a campus in Tinton Falls that would include a center operated by the Rutgers Cancer Institute of New Jersey. Read More
Also syndicated in:
Prestigious Scholarships
The Lustgarten Foundation Announces Recipients of Career Development Awards for Pancreatic Cancer Research in Honor of Ruth Bader Ginsburg and John Robert Lewis
Article image
Apr 13 | Online Publication  |  Reach: 552,831 | Sentiment : Positive
Share article :  |  |  | 
EurekAlert! - Pingping Hou, PhD, of Rutgers Cancer Institute of New Jersey and Edwin Manuel, PhD, of the City of Hope, were announced at the American Association for Cancer Research Annual Meeting 2022 as the latest recipients of the Lustgarten Foundation-AACR Career Development Awards for Pancreatic Cancer Research in Honor of Ruth Bader Ginsburg and John Robert Lewis. Read More
Recent FDA Approvals Signal Revolution in HER2+ Breast Cancer Treatment
Apr 11 | Online Publication| Ashling Wahner  |  Reach: 121,472 | Sentiment : Positive
Share article :  |  |  | 
OncLive - In an interview with OncLive®, George, medical oncologist, Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey, discussed the variety of innovative HER2-positive breast cancer treatment options that have recently been approved or are undergoing investigation in clinical trials to broaden the standards of care for patients in this subgroup. George: There have been a lot of new drug approvals, especially in the last 3 years. HER2-positive breast cancer is one of the aggressive subtypes of breast cancer, and patients have poor survival [outcomes]. Read More
Dr. George on Efforts To Address Unmet Needs in HER2-Low Breast Cancer
Apr 01 | Online Publication| Mridula George  |  Reach: 121,473 | Sentiment : Neutral
Share article :  |  |  | 
OncLive - Mridula George, MD, medical oncologist, Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, assistant professor of medicine, Rutgers Robert Wood Johnson Medical School, discusses efforts to address unmet needs in HER2-low breast cancer. The phase 3 DESTINY-Breast04 trial investigated fam-trastuzumab deruxtecan-nxki (Enhertu) vs. physician’s choice of chemotherapy in patients with unresectable or metastatic HER2-low breast cancer. This study was pivotal because there is currently no treatment for this subgroup of patients, George says. Read More
Also syndicated in:
NewsBeezer
Syndicated Reach: TM - 479,762
EP. 6B: Benefits of Using Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer in Clinical Practice
Apr 26 | Online Publication| Jyoti Malhotra  |  Reach: 68,912 | Sentiment : Neutral
Share article :  |  |  | 
Targeted Oncology - In the third video of the series, Dr. Jyoti Malhotra from the Rutgers Cancer Institute of New Jersey shares expert insights on the benefits of using trilaciclib in clinical practice including considerations for chemotherapy treatment efficacy and patient quality of life. Trilaciclib was approved in 2021 for the treatment of patients with extensive-stage small-cell lung cancer who are receiving chemotherapy with either platinum-etoposide or topotecan. Through the approval of this drug, we now have an option to prevent chemotherapy-related myelosuppression in these patients, not just for preventing neutropenia but also anemia and thrombocytopenia because trilaciclib impacts and targets trilineage hematopoiesis, which is a big advantage. Read More
Oncotarget: Mutational Burden in Lung Cancer Studied in Multisite Cohort
Apr 25 | Online Publication  |  Reach: 552,832 | Sentiment : Neutral
Share article :  |  |  | 
EurekAlert! - A trending research paper, entitled, “Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study,” was published in Oncotarget on January 31, 2022, by researchers from University of Utah, University of Minnesota Duluth, Huntsman Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, Baptist Health Medical Group, MetroHealth Medical Center, Rutgers Cancer Institute of New Jersey, University of Southern California, Saint Luke’s Cancer Institute, University of Kentucky, and Bristol Myers Squibb. Read More
Also syndicated in:
Oncotarget
How To Access Cancer Education Resources
Article image
Apr 04 | Online Publication  |  Reach: 10,314,250 | Sentiment : Neutral
Share article :  |  |  | 
New Jersey Patch - Rutgers Cancer Institute of New Jersey's Resource and Learning Center provides patients and family members with important educational information. At Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, your cancer care team is here for you answering every question and supporting every decision, but it's still important to learn as much as you can about your cancer diagnosis so you can feel empowered along your journey. The RLC is staffed by a full time medical librarian, Janet Lasin, MLS, BS, who is able to provide information on treatment options, symptom management, alternative and complementary therapies, nutrition and support services. Read More
Also syndicated in:
HealthNewsDigest.com
Syndicated Reach: TM - 266
Testicular Cancer: It’s Time To Talk
Apr 04 | Online Publication  |  Reach: 10,314,250 | Sentiment : Neutral
Share article :  |  |  | 
New Jersey Patch - According to data from the National Cancer Institute, the median age of a cancer diagnosis is 66 years, but certain cancers occur more commonly in young people. Thomas L. Jang, MD, MPH, FACS, associate chief of urologic oncology and director of the Testicular Cancer Program at Rutgers Cancer Institute of New Jersey and associate professor of surgery and program director for the Urology Residency Program at Rutgers Robert Wood Johnson Medical School, shares more. "Though testicular cancer can impact males of any age, it generally affects young men who are in their 20s and 30s. The average age at the time of diagnosis of testicular cancer is about 33 according to the American Cancer Society," he says. Read More
Also syndicated in:
HealthNewsDigest.com
Syndicated Reach: TM - 266
Keeping a Close Eye on Pancreatic Cysts
Apr 04 | Online Publication  |  Reach: 1,493,932 | Sentiment : Positive
Share article :  |  |  | 
TAPinto.net - An innovative program at Cooperman Barnabas Medical Center identifies cysts on the pancreas before they can develop into cancer. Russell C. Langan, MD, a Director of Surgical Oncology for RWJBarnabas Health/Rutgers Cancer Institute of New Jersey and the Chief of Surgical Oncology and Hepatopancreatobiliary Surgery at CBMC, explains. Read More
Recommended by Fullintel Analysts

You are currently subscribed as info@fullintel.com. For further assistance, please contact Customer Service at support@fullintel.com

Unsubscribe   |   Privacy Policy

Copyright 2022 Fullintel, LLC. All Rights Reserved.

Powered by
Fluid structures